PFE - Pfizer Inc.
| Previous Close | 43.07 |
| Open | 43.17 |
| Bid | 43.18 x 1000 |
| Ask | 43.19 x 800 |
| Day's Range | 43.10 - 43.49 |
| 52 Week Range | 36.00 - 46.47 |
| Volume | 3,660,077 |
| Avg. Volume | 21,548,356 |
| Market Cap | 239.782B |
| Beta (3Y Monthly) | 0.43 |
| PE Ratio (TTM) | 22.18 |
| EPS (TTM) | 1.95 |
| Earnings Date | Jul 30, 2019 |
| Forward Dividend & Yield | 1.44 (3.34%) |
| Ex-Dividend Date | 2019-05-09 |
| 1y Target Est | 45.57 |
- TheStreet.com•1 hour ago
2 Midcaps to Watch Should Pfizer-Array Deal Spark M&A Fever in Biotech Land
"Merger Monday" finally lived up to its billing this week in Biotech Land. announced just before the opening bell Monday that it was acquiring oncology concern Array Biopharma Inc. Pfizer paid a buyout premium of more than 60% to purchase Array.
- Zacks•2 hours ago
Big Drugmakers That May Tread the M&A Path After Pfizer
There has been a flurry of M&A deal announcements this year in the drug industry. Here we discuss three big drug/biotech companies, which may make the next M&A move.
- PR Newswire•17 hours ago
SHAREHOLDER ALERT: WeissLaw LLP Investigates Array BioPharma Acquisition
NEW YORK, June 18, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Array BioPharma ("Array" or the "Company") (ARRY) in connection with the proposed acquisition of the Company by Pfizer Inc. ("Pfizer") (PFE).
- Zacks•18 hours ago
Pfizer (PFE) Gains But Lags Market: What You Should Know
Pfizer (PFE) closed at $43.08 in the latest trading session, marking a +0.45% move from the prior day.
- Motley Fool•19 hours ago
Papa John’s Auditor Swap Is Not a Good Look
The pizza purveyor once again proves itself incapable of not making matters worse, this time with a very poorly timed change.
- Zacks•yesterday
Protalix (PLX) Completes Enrollment in Fabry Disease Study
Protalix (PLX) closes enrollment in the late-stage study on PRX-102, currently being developed for the treatment of patients with Fabry disease.
- Business Wire•yesterday
Pfizer Invites Public to View and Listen to Webcast of July 30 Conference Call with Analysts
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, July 30, 2019. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2019 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors.
- Zacks•yesterday
Pfizer-Array Biopharma Deal Bump Up Biotech ETFs
Pfizer struck a deal to acquire the cancer drugmaker Array Biopharma for $11 billion in an all-cash consideration.
- Investopedia•yesterday
Cancer Therapy Stocks Soar After Pfizer Deal
Cancer therapy stocks rallied after Pfizer made a deal to boost its oncology offerings. These industry players may also be takeover targets.
- Zacks•yesterday
Pfizer to Buy Array BioPharma, Broaden Cancer Portfolio
Pfizer (PFE) offers $48 per share to buy Array BioPharma and strengthen its cancer portfolio.
- Markit•yesterday
See what the IHS Markit Score report has to say about Pfizer Inc.
Pfizer Inc NYSE:PFEView full report here! Summary * Perception of the company's creditworthiness is negative * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for PFE with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting PFE. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold PFE had net inflows of $8.41 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swap | NegativeThe current level displays a negative indicator. PFE credit default swap spreads are within the middle of their range for the last three years.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Motley Fool•yesterday
3 Big Drugmakers Most Likely to Make Acquisitions After Pfizer's Surprise Deal
Pfizer could be only the first of several to spend billions buying smaller biotech.
- MarketWatch•yesterday
Shares of cancer-therapy companies skyrocket after Pfizer acquisition news
Shares of gene-therapy companies shot up on Monday after Pfizer Inc. announced it would acquire cancer drug maker Array BioPharma Inc. in a deal worth up to $11.4 billion.
- Financial Times•yesterday
NHS and life sciences sector failing to work together
Mutual suspicions are preventing Britain’s National Health Service and life sciences companies from working together effectively, according to a new report. Research by the NHS Confederation and the Association of the British Pharmaceutical Industry (ABPI) found that some NHS managers are actively telling staff not to deal with industry, while others keep joint projects with life sciences companies “below the radar” because of fears about private sector involvement in the taxpayer funded system. Niall Dickson, chief executive of the NHS Confederation, said that as the NHS increasingly managed people with multiple conditions and sought to mitigate demand in the hospital sector, “technology in the wider sense, and life sciences in particular, are going to be utterly critical for the NHS over the next 10 or 15 years”.
- Reuters•yesterday
PRESS DIGEST - Wall Street Journal - June 18
- Motley Fool•2 days ago
What Happened in the Stock Market Today
Acquisitions made headlines, with Pfizer buying Array BioPharma and a private investor picking up Sotheby's.
- Motley Fool•2 days ago
Why Pfizer's Acquisition of Array BioPharma Won't Pay Off Anytime Soon
The big drugmaker is spending more than $11 billion for the cancer-drug specialist.
- Investor's Business Daily•2 days ago
How Pfizer's $11.4 Billion Takeover Of Array Signals More Mergers
Dow Jones component Pfizer is buying biotech company Array BioPharma in an $11.4 billion deal that reaps the rewards of two approved cancer treatments. Array stock soared to a record high.
- InvestorPlace•2 days ago
Dow Jones Today: Almost a Case of the Mondays
On the surface, the gains notched by the major U.S. equity benchmarks to start the week were not all that impressive. The Nasdaq Composite led the way, climbing 0.62%, while the S&P 500 and the Dow Jones Industrial Average each finished higher by 0.09%.Source: Shutterstock However, there were pockets of excitement throughout the market today, helped by the return of Merger Monday. Dow component Pfizer (NYSE:PFE), one of the largest U.S. pharmaceuticals companies, is looking to bolster its oncology offerings by acquiring cancer treatment maker Array BioPharma (NASDAQ:ARRY) for $48 a share in cash, putting an enterprise value of about $11.4 billion on the company.Pfizer has one of the larger cash stockpiles among the major U.S. pharmaceuticals companies and checks many of the quality boxes. However, there are some concerns the Array deal could be credit negative.InvestorPlace - Stock Market News, Stock Advice & Trading TipsCredit ratings aside, traditional pharmaceuticals companies need growth, and buying makers of cancer drugs is one avenue for delivering that growth. Other ChatterApple (NASDAQ:AAPL) stock, always a widely watched bellwether as it is the largest technology name in the Dow, traded modestly higher Monday although some analysts expressed concern about the impact of the China trade war on the stock and how the company is positioned for a fuller 5G rollout next year. * 7 Top-Rated Biotech Stocks to Invest In Today "JPMorgan analyst Samik Chatterjee cut his forecast for iPhone shipments for the next few quarters by 4%, and trimmed his price target on the stock to $233 from $235," reports Barron's. "But he maintains an Overweight rating on the shares, asserting that the trade tensions are likely to be resolved."Sticking with Dow technology names for a moment, Intel (NASDAQ:INTC), one of the largest semiconductor makers, is trying to snap out of a funk that has the stock down nearly 15% in the current quarter. Much of that tumble is attributable to semiconductor companies' sensitivity to the trade war with China, but for long-term investors, there are reasons to be optimistic about Intel."We concede that 2019 will be strenuous for Intel because of macro weakness, U.S.-China tensions, and share loss, but overall revenue growth should eventually stabilize," said Morningstar in a recent note. "As Intel gets back on track in 2020 with its 10-nm Ice Lake server parts, we think its data center group, or DCG, will enjoy average top-line growth of 10% through 2023."Boeing (NYSE:BA), a frequent guest in this space and the Dow's largest component, was the blue-chip index's best performer Monday, adding 2.2%. The company said it has no plans to rename the controversial 737 max passenger jet.At the Paris Airshow Monday, the aerospace giant boosted its 20-year demand forecast for passenger jets to $6.8 trillion, up from a previous estimate of $6.3 trillion."The world's largest planemaker said at the Paris Airshow it expected 44,040 new airplane deliveries over the next two decades, up from the roughly 43,000 it forecast a year ago," according to Reuters. Bottom Line on the Dow Jones TodayOverall, a little under half of the Dow's 30 components closed higher today, hardly a great percentage and risks remain for investors to consider. Looking out to later in June, FedEx Corp. (NYSE:FDX) reports fiscal fourth-quarter results on June 25, and while the freight shipping company is not a member of the Dow Jones Industrial Average, it is a member of the Dow Jones Transportation Index, and a bellwether stock at that.Mired in a slump that has seen the shares slide almost 5% this month, FedEx stock lost another half percent Monday after JPMorgan lowered its price target on the stock to $184 from $202. Tennessee-based FedEx has been a guidance offender multiple times over the past year and it appears that bad news is poised to continue.Again, FedEx is not a Dow stock, nor is it the largest company in the U.S. Not even close, but transportation names are historically accurate gauges of economic sentiment the market's tolerance for risk so there could be some tests coming for stocks before June ends.As of this writing, Todd Shriber did not own any of the aforementioned securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * The 7 Best Tech Stocks to Buy for the Second Half of 2019 * 7 Top-Rated Biotech Stocks to Invest In Today * 4 Semiconductor Stocks to Sell Compare Brokers The post Dow Jones Today: Almost a Case of the Mondays appeared first on InvestorPlace.
- TheStreet.com•2 days ago
Stocks End Slightly Higher in Cautious Trading Ahead of Federal Reserve Meeting
The Dow Jones Industrial Average ended moderately higher Monday as investors moved cautiously heading into this week's Federal Reserve meeting and weighed renewed tariff threats from the White House. Facebook is Real Money's Stock of the Day. Stocks ended slightly higher on Monday as investors adopted a cautious stance going into this week's Federal Reserve meeting and amid renewed tariff threats from the White House.
- American City Business Journals•2 days ago
Pfizer acquires Array in 2nd major Boulder bioscience merger this month
Array BioPharma Inc. (Nasdaq: ARRY) has been acquired by Pfizer Inc. (NYSE: PFE). The Boulder-based biopharmaceutical firm focused on the commercialization of small molecule medicines to treat cancer and other diseases is being acquired for about $11.4 billion, or $48 per share. Upon approval by each company's board and the close of the deal, Array’s employees will join Pfizer and will continue to be located in Boulder.
- Reuters•2 days ago
US STOCKS-Faith in the Fed nudges Wall Street higher
Wall Street edged higher on Monday, supported by Facebook, Amazon and Apple, as investors awaited a key Federal Reserve meeting that is expected to lay the groundwork for an interest rate cut later this year. The U.S. central bank is expected to leave borrowing costs unchanged at its two-day policy meeting starting Tuesday, but its statement will provide insight into the impact of the U.S.-China trade war, President Donald Trump's calls for a rate cut and weaker economic data. With investors expecting a rate cut as early as July, the S&P 500 index has risen 5% this month after tumbling in May due to fears about the U.S.-China trade war.
- InvestorPlace•2 days ago
5 Top Stock Trades for Tuesday: FB, NFLX, GILD, TSLA
Indices tiptoed higher on Monday, but investors are waiting to hear what the Federal Reserve has to say later this week before making any drastic moves. That's not stopping some companies from pouncing though, as M&A continues to be a theme over the last few weeks. Let's let a deal kick off our top stock trades for Tuesday. Top Stock Trades for Tomorrow 1: Pfizer Click to EnlargePfizer (NYSE:PFE) stock is in the news following its $11.4 billion acquisition of Array Biopharma (NASDAQ:ARRY) for $48 per share. The deal sent the latter up by more than 50%, while the former is trying to breakout over resistance as well.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Top-Rated Biotech Stocks to Invest In Today PFE stock has been a better sell than buy up near $43 to $43.50, and a solid buy down near $40. That said, with shares holding up on news of this deal -- actually eking out a gain on Monday -- and trading north of all three of its major moving averages, it looks okay on the long side.If it can clear $43.50 though, it WILL be setting up as a breakout. Over that and $45 is in sight, with even higher prices possible should PFE push through. Top Stock Trades for Tomorrow 2: Gilead Sciences Click to EnlargeThe PFE deal has biotech trading higher on the day and Gilead Sciences (NASDAQ:GILD) is no exception. Shares are up more than 1% on the day, as GILD stock pushes through its 200-day moving average.The 200-day happens to overlap with $76 range resistance, so perhaps this area knocks the stock down once more. However, if GILD can push through, a run up to $70 is possible. If it is resistance, a decline down to the 50-day is expected, with a possible decline down to uptrend support being possible. Top Stock Trades for Tomorrow 3: Tesla Click to EnlargeShares of Tesla (NASDAQ:TSLA) are moving really well on Monday, up over 5% on the day and up over $225. It puts the 50-day moving average in play currently at $231.45, as well as channel resistance near $235 to $240.Should Tesla rally this far, it would be a logical place to book profits for traders. Above it and former range support between $250 to $260 comes into play. In May that area acted as resistance for TSLA.On a pullback -- either from current levels or after tagging resistance -- see that channel support (blue line) holds. Ideally though, the 20-day will act as support for Tesla. Top Stock Trades for Tomorrow 4: Facebook Click to EnlargeThe big blue box on the Facebook (NASDAQ:FB) chart above represents the gap that was created from the company's disappointing quarterly results 11 months ago.Shares have pushed into this gap twice, in August 2018 and Q2 2019. Neither time has the stock been able to "fill" the gap all the way back up.With FB stock now jumping higher though, is the third time a charm? Maybe. Shares have climbed aggressive off the $160 lows and 200-day moving average, up almost $30 per share in just a few weeks. FB previously topped out near $196 and needs to push through this mark, as well as prior uptrend support (blue line) to fill the gap even more.The 61.8% is at $182.34, while the 50-day is at $182.18. So long as it holds $182, FB looks okay on the long side. Below and it can get a little choppier. Top Stock Trades for Tomorrow 5: Netflix Click to EnlargeNetflix (NASDAQ:NFLX) stock has been highly responsive to this $340 to $342 level. Buyers gobble it up each time NFLX dips in this area of range support. * The 7 Best Tech Stocks to Buy for the Second Half of 2019 That makes it a simple setup, and simple is what we like when it comes to trading. Below the 200-day and traders can cut their losses when dip-buying into this area. Now up a quick 10 points, let's see how NFLX handles the 50-day moving average. Above it could send Netflix to range resistance up near $380.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell did not hold a position in any of the aforementioned securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * The 7 Best Tech Stocks to Buy for the Second Half of 2019 * 7 Top-Rated Biotech Stocks to Invest In Today * 4 Semiconductor Stocks to Sell Compare Brokers The post 5 Top Stock Trades for Tuesday: FB, NFLX, GILD, TSLA appeared first on InvestorPlace.
- Barrons.com•2 days ago
Pfizer Is Buying Array BioPharma, Seeking to Broaden Lineup of Cancer Drugs
The pharmaceutical company Pfizer said it would buy Array BioPharma, a maker of cancer drugs, for $48 a share in cash.
